NasdaqCM - Nasdaq Real Time Price USD

Veru Inc. (VERU)

0.5035

-0.0186

(-3.56%)

At close: May 9 at 4:00:00 PM EDT

0.5200

+0.02

+(3.28%)

After hours: May 9 at 7:36:40 PM EDT

Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial ...

Veru Inc (VERU) reports positive Phase 2B study results for Novosarm, but faces financial hurdles with a net loss and need for additional capital.

GuruFocus.com 2 days ago

VERU
-3.56%
Veru Participates in a Virtual Investor KOL Connect Segment

-- Moderated discussion with preeminent obesity expert, Louis J. Aronne, MD, FACP and Mitchell Steiner, M.D., F.A.C.S, President, CEO, and Founder, of Veru -- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced the release of a Virtual Investor KOL segment featuring Louis J. Aronne, MD, FACP. As part of the se

GlobeNewswire 3 days ago

VERU
-3.56%
Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

--Unblinded safety data from Phase 2b QUALITY study expected in the second quarter of calendar 2025 -- --Topline efficacy and safety data for Phase 2b extension maintenance study expected in the second quarter of calendar 2025 -- --With positive Phase 2b QUALITY study, Veru plans for end of Phase 2 meeting with FDA to discuss Phase 3 clinical program -- --Company to host conference call and webcast today at 8:00 a.m. ET-- MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a la

GlobeNewswire 3 days ago

VERU
-3.56%
Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

MIAMI, May 01, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced it will host a conference call and audio webcast on Thursday, May 8, 2025, at 8:00 a.m. ET to discuss its fiscal 2025 second quarter financial results and to provide a business update. The audio webcast will be accessible under the Home page and Investors page of

GlobeNewswire 10 days ago

VERU
-3.56%
Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

MIAMI, FL, April 16, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that the Company will present at the 2nd Annual GLP-1-Based Therapeutics Summit, taking place April 29 - May 1, 2025, in Boston, Massachusetts. Presentation Title: Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass and Physical Function in Older

GlobeNewswire 25 days ago

VERU
-3.56%
Compass Therapeutics And 2 More Compelling Penny Stocks

As the U.S. markets navigate a period of volatility, with the S&P 500 and Nasdaq recently closing higher despite economic uncertainties, investors are keenly observing potential opportunities in various sectors. Penny stocks, often associated with smaller or emerging companies, continue to capture interest due to their affordability and growth potential. While the term may seem outdated, these stocks can offer significant value when backed by strong financials and clear growth strategies. In...

Simply Wall St. last month

CMPX

VERU
-3.56%

MVST
Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

MIAMI, FL, March 31, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will participate in a fireside chat at the upcoming Jones Healthcare and Technology Innovation Conference, in Las Vegas, Nevada, on April 9, 2025 at 3:00 pm – 3:20 pm Paci

GlobeNewswire last month

VERU
-3.56%
Here's Why Veru (VERU) Looks Ripe for Bottom Fishing

After losing some value lately, a hammer chart pattern has been formed for Veru (VERU), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks last month

VERU
-3.56%
Down -9.23% in 4 Weeks, Here's Why Veru (VERU) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Veru (VERU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks 2 months ago

VERU
-3.56%
3 US Penny Stocks With Market Caps Under $300M To Consider

The U.S. stock market recently experienced a sharp decline after two days of record highs for the S&P 500, with major indices like the Dow Jones and Nasdaq also seeing significant drops. For investors interested in smaller or newer companies, penny stocks remain a relevant area of investment despite their vintage name. These stocks, often representing firms with solid financial foundations, can offer unique opportunities for growth and value that larger companies might overlook.

Simply Wall St. 2 months ago

ISPR

VERU
-3.56%

CLAR
Veru Inc (VERU) Q1 2025 Earnings Call Highlights: Strategic Shifts and Clinical Progress Amid ...

Veru Inc (VERU) advances its biopharmaceutical pipeline with promising clinical results while navigating financial hurdles and strategic divestments.

GuruFocus.com 2 months ago

VERU
-3.56%
Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

--Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater fat loss and improvement of physical function-- -- The Independent Data Monitoring Committee met this week on February 10, 2025 to evaluate the unblinded safety Phase 2b QUALITY data and recommended to continue the QUALITY extension study as designed-- --Topline results of the Phase 2b extension m

GlobeNewswire 2 months ago

VERU
-3.56%
Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced it will host a conference call and audio webcast on Thursday, February 13, 2025, at 8:00 a.m. ET to discuss its fiscal 2025 first quarter financial results and to provide a business update. The audio webca

GlobeNewswire 3 months ago

VERU
-3.56%
Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru, will present at the upcoming virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 1

GlobeNewswire 3 months ago

VERU
-3.56%
Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

-- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on average lost 71% less lean mass than patients receiving WEGOVY alone -- -- Patients on Enobosarm on average lost 27% more fat mass than patients receiving WEGOVY alone – -- Enobosarm improved body composition as mean total body weight loss was similar compared to subjects receiving WEGOVY alone -- -- Enob

GlobeNewswire 3 months ago

VERU
-3.56%
What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now?

Does Veru Inc. (VERU) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks 3 months ago

VERU
-3.56%
3 US Penny Stocks With Market Caps Under $200M To Consider

The U.S. stock market has shown resilience, with the Dow Jones Industrial Average rising on a softer-than-expected Producer Price Index report and a dip in oil prices. For those interested in exploring smaller or newer companies, penny stocks—despite their somewhat outdated name—remain an intriguing investment area. These stocks can offer a mix of affordability and growth potential, especially when backed by strong financials, making them appealing to investors seeking under-the-radar...

Simply Wall St. 3 months ago

VERU
-3.56%

TORO

PETS
Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline

Veru Inc. (NASDAQ:VERU) shares jumped on Tuesday after the company disclosed the sale of its FC2 Female Condom (Internal Condom) business to clients managed by Riva Ridge Capital Management LP and co-investors for $18 million. As a result of the FC2 business sale, Veru’s workforce will be reduced by approximately 90%, from 210 employees to 22. After deducting the change of control premium to SWK Funding LLC under the company's Residual Royalty Agreement, along with customary transaction fees, Ve

Benzinga 4 months ago

VERU
-3.56%
Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

MIAMI, FL, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that it has sold its FC2 Female Condom® (Internal Condom) business to clients managed by Riva Ridge Capital Management LP, a New York City-based investment management firm as well as other co-investors, fo

GlobeNewswire 4 months ago

VERU
-3.56%
Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates

Veru (VERU) delivered earnings and revenue surprises of 14.29% and 86.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 4 months ago

VERU
-3.56%

Performance Overview

Return	VERU	S&P 500 (^GSPC)
YTD	-22.54%	-3.77%
1-Year	-63.25%	+8.55%
3-Year	-93.82%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Veru Inc. (VERU)

Veru Inc (VERU) Q2 2025 Earnings Call Highlights: Promising Clinical Results Amid Financial ...

Veru Participates in a Virtual Investor KOL Connect Segment

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Compass Therapeutics And 2 More Compelling Penny Stocks

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Here's Why Veru (VERU) Looks Ripe for Bottom Fishing

Down -9.23% in 4 Weeks, Here's Why Veru (VERU) Looks Ripe for a Turnaround

3 US Penny Stocks With Market Caps Under $300M To Consider

Veru Inc (VERU) Q1 2025 Earnings Call Highlights: Strategic Shifts and Clinical Progress Amid ...

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

Veru to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now?

3 US Penny Stocks With Market Caps Under $200M To Consider

Veru Sells FC2 Condom Business For $18 Million, Focuses On Biopharma Pipeline

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Veru Inc. (VERU) Reports Q4 Loss, Tops Revenue Estimates

Performance Overview